Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-01-12 08:00 |
Biophytis prévoit de prendre les mesures appropriées après avoir reçu l’avis d…
|
French | 133.0 KB | ||
| 2023-01-05 08:00 |
Biophytis annonce sa participation au mois de janvier à deux conférences invest…
|
French | 138.7 KB | ||
| 2022-12-01 08:03 |
BIOPHYTIS ORGANISE UN WEBCAST EN PRÉSENCE DE KEY OPINION LEADERS (KOL) SUR LES …
|
French | 203.0 KB | ||
| 2022-11-03 10:42 |
Biophytis rapporte l’analyse post-hoc positive de l’étude de phase 2-3 COVA so…
|
French | 358.6 KB | ||
| 2022-11-03 08:00 |
Biophytis rapporte l’analyse post-hoc positive de l’étude de phase 2-3 COVA sou…
|
French | 507.8 KB | ||
| 2022-10-31 23:00 |
Biophytis publie ses principaux agrégats financiers au 30 juin 2022, annonce un…
|
French | 323.6 KB | ||
| 2022-10-26 08:00 |
Biophytis reçoit une notification du Nasdaq
|
French | 189.5 KB | ||
| 2022-09-15 08:00 |
Biophytis participe à la 24ème Global Investment Conference de HC Wainwright à …
|
French | 217.3 KB | ||
| 2022-04-22 17:44 |
Rapport Financier Annuel 2021
|
French | 4.2 MB | ||
| 2021-12-16 08:00 |
Rencontre prévue avec la FDA pour faire avancer le développement de Sarconeos (…
|
French | 488.6 KB | ||
| 2021-11-22 23:00 |
Biophytis obtient une nouvelle structure de prêt de 10 M€ avec Kreos Capital
|
French | 135.9 KB | ||
| 2021-11-15 08:00 |
Biophytis annonce la reprise du recrutement dans les centres aux Etats-Unis pou…
|
French | 222.6 KB | ||
| 2021-10-29 08:00 |
Biophytis Publie les Résultats Financiers Corrigés pour les Périodes Antérieure…
|
French | 306.5 KB | ||
| 2021-10-29 08:00 |
Biophytis to Report Restated Financial Statements for Previous Periods and as o…
|
English | 320.7 KB | ||
| 2021-10-29 01:22 |
Rapport financier semestriel au 30 juin 2021
|
French | 828.7 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
